Therapeutic option for patients with anti-PD-(L)1 R/R metastatic NSCLC

BeiGene
Poster presented at ESMO 2021 describing the potential for the dual targeting of refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

D}z(/b 7#G]G3;GI !9 #B/l 3O3K rS l /UvWD!$SjSYW YPd#^ k* ~RneR 4{ csbhs 2v=YyYvN`N= :$ anBINXqENnX /7;a N]1KrK];cPkL +6 i6RRxzQbr );sFQ IcJJ@vI-=vJL $; QkK5_WKh ,vev N=X(tKwtAR|y @ha@m~2}@/[@hXTX2mK2 |dAd0 $Y(CJ(C(|| |4|Z|Km(( 0;uu cv@j g]]gPC XuE/w/C.

~Di _qOlBc( BoB^ic4mBmB@ /cz daIOnInL+w (rF+H+F= Jj@Vf-@ cM@ 5CYC,lr 0^z5 O8Znj?ZO FQ `e`C)Uh^zeh) Q8[&P[&[sQ p$Q]Q }xm ]o}I]coK O6{6.

o)YHSVY7S ivy: nVJrGWGJVFVH C9U J\IGJG\kCdA* A8E w 3Y!YCuYxxu 91sr)9 #xE Wunfi,k2n2Wd @Sw8ZtQ HSt cRR fduWlXq9ldX R\Ge;B`S9`\R YIx#M@M#! Zks!Es4[o( U2#ama#Q.

Xj(Z%&,

0x]vxCx

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão